An international comparative policy analysis of opioid use disorder treatment in primary care across nine high-income jurisdictions
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved..
BACKGROUND: Opioid use disorder (OUD) and opioid-related harms are current health priorities in many high-income countries such as Canada. Opioid agonist therapy (OAT) is an effective evidence-based treatment for OUD, but access is often limited.
AIMS: To describe and compare OUD treatment policies across nine international jurisdictions, and to understand how they are situated within their primary care and health systems.
METHODS: Using policy documents, we collected data on health systems, drug use epidemiology, drug policies, and OUD treatment from Australia, Canada, France, Germany, Ireland, Portugal, Sweden, Switzerland, and Taiwan. We used the health system dynamics framework and adapted definitions of low- and high-threshold treatment to describe and compare OUD treatment policies, and to understand how they may be shaped by their health systems context.
RESULTS: Broad similarities across jurisdictions included the OAT pharmacological agents used and the need for supervised dosing; however, preferred OAT, treatment settings, primary care and specialist physicians' roles, and funding varied. Most jurisdictions had elements of lower-threshold treatment access, such as the availability of treatment through primary care and multiple OAT options, but the higher-threshold criteria of supervised dosing.
CONCLUSIONS: From the Canadian perspective, there are opportunities to improve accessibility of OUD care by drawing on how different jurisdictions incorporate multidisciplinary care, regulate OAT medications, remunerate healthcare professionals, and provide funding for services.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
Health policy (Amsterdam, Netherlands) - 141(2024) vom: 23. Feb., Seite 104993 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chiu, Kellia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesics, Opioid |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.healthpol.2024.104993 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367276976 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367276976 | ||
| 003 | DE-627 | ||
| 005 | 20240229154923.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240119s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.healthpol.2024.104993 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM367276976 | ||
| 035 | |a (NLM)38237202 | ||
| 035 | |a (PII)S0168-8510(24)00003-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chiu, Kellia |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An international comparative policy analysis of opioid use disorder treatment in primary care across nine high-income jurisdictions |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Opioid use disorder (OUD) and opioid-related harms are current health priorities in many high-income countries such as Canada. Opioid agonist therapy (OAT) is an effective evidence-based treatment for OUD, but access is often limited | ||
| 520 | |a AIMS: To describe and compare OUD treatment policies across nine international jurisdictions, and to understand how they are situated within their primary care and health systems | ||
| 520 | |a METHODS: Using policy documents, we collected data on health systems, drug use epidemiology, drug policies, and OUD treatment from Australia, Canada, France, Germany, Ireland, Portugal, Sweden, Switzerland, and Taiwan. We used the health system dynamics framework and adapted definitions of low- and high-threshold treatment to describe and compare OUD treatment policies, and to understand how they may be shaped by their health systems context | ||
| 520 | |a RESULTS: Broad similarities across jurisdictions included the OAT pharmacological agents used and the need for supervised dosing; however, preferred OAT, treatment settings, primary care and specialist physicians' roles, and funding varied. Most jurisdictions had elements of lower-threshold treatment access, such as the availability of treatment through primary care and multiple OAT options, but the higher-threshold criteria of supervised dosing | ||
| 520 | |a CONCLUSIONS: From the Canadian perspective, there are opportunities to improve accessibility of OUD care by drawing on how different jurisdictions incorporate multidisciplinary care, regulate OAT medications, remunerate healthcare professionals, and provide funding for services | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Health policy | |
| 650 | 4 | |a Health systems | |
| 650 | 4 | |a Opiate substitution therapy | |
| 650 | 4 | |a Opioid-related disorders | |
| 650 | 4 | |a Policy making | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 700 | 1 | |a Pandya, Saloni |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Manu |e verfasserin |4 aut | |
| 700 | 1 | |a Hooimeyer, Ashleigh |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Sud, Abhimanyu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health policy (Amsterdam, Netherlands) |d 1984 |g 141(2024) vom: 23. Feb., Seite 104993 |w (DE-627)NLM083840788 |x 1872-6054 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2024 |g day:23 |g month:02 |g pages:104993 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.healthpol.2024.104993 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2024 |b 23 |c 02 |h 104993 | ||